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Abstract
It is increasingly suggested that shortages in the supply chain for human blood could
be met by the development of techniques to manufacture human blood ex vivo.
These techniques fall broadly under the umbrella of synthetic biology. We examine
the biopolitical context surrounding the ex vivo culture of red blood cells through
the linked concepts of alienation, immunity, bio-value and biosecuritization. We
engage with diverse meanings of synthetic blood, and questions about how the
discourses of biosecurity and privatization of risk are linked to claims that the
technology will address unmet needs and promote social justice. Through our
discussion we contrast communitarian ideas that culturing red blood cells ‘extends
the gift’ of adult blood donation with understandings of the immunitary logics that
underpin the cord-blood economy.
Keywords
alienation, biosecuritization, bio-value, blood economies, cultured red blood cells,
gift relations, immune politics, stem cells, synthetic biology
The development of techniques for the culturing of red blood cells,
sometimes called synthetic or manufactured red blood cells, is part of
a wider emergence of regenerative medicine as an expanding field
attracting public and private investment. The manufacturing of red
blood cells and their entry into national and international blood
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economies present possibilities for the extension of both government
and private capital into the functioning of biological systems; an
amplification of both governance over, and economization of, life
itself with aims that include both the regeneration of economies (in
the broad sense) and bodies (Cooper, 2008; Kent, 2012; Rose, 2007;
Waldby and Mitchell, 2006). In this article, we first describe the
development of cultured red blood cell technology and situate this
within the context of wider efforts to address ‘unmet need’ within
blood economies. Second, we interrogate the political context and
framing of these efforts, and examine suggestions that ‘synthetic
blood’ potentially weakens kinship bonds and threatens social soli-
darity (Weston, 2013). In so doing we hope to contribute to contem-
porary discussions of ‘new biologies’ and the continued
‘entanglement of politics and biology’ (Jamieson, 2016) in the con-
text of synthetic biology.
Recognition of the ways in which politics and biology are
‘entangled’ implies asking in what ways new blood technologies
could transform social relations, political divisions and existing
inequalities, and also in what ways the new technologies are shaped
by them. For us, key questions concerning cultured red blood cells
include: How are ‘needs’ constructed by the technology within the
context of current blood economies? Who might benefit from this
technology and how might these benefits be distributed? How do
models of immunitary thinking assist us in mapping the biopolitics
of cultured red blood cells? We think that the institutional context for
the development of cultured red blood cell technology and the dis-
tinction between welfarist and non-welfarist immuno-politics is cen-
tral to situating cultured red blood cells within blood economies. Our
focus is on the current investment in this technology in the UK’s
National Health Service (NHS) Blood and Transplant service, an
executive non-departmental public body of the UK’s Department
of Health. We acknowledge, however, that analysis of the blood
economy via simple public vs private or welfarist vs non-welfarist
dichotomies is problematic.
In this regard, the work of Italian philosopher Roberto Esposito
(2010 [1998]) has been influential in recent discussions of blood and
cord-blood economies. Esposito’s account of the difference between
the political concepts of community (communitas) and immunity
(immunitas) offers an alternative to the binary thinking of shared
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public resources vs private individualized markets. In contrast to
bioethical assumptions that blood donation construed as a gift creates
community, Esposito’s view of community stresses the creation of
bonds characterized by obligation and moral debt. Immunity, on the
contrary, offers protection or release from political obligations to
others and in doing so can serve to safeguard the life of the one
granted immunity.
Drawing on his ideas, Brown and Williams (2015) analyse the
international exchange of units of cord-blood-derived stem cells for
transplantation through the lens of an immunitary regime where
precise matching requires a network of linked repositories of material
and data. They say this ‘cosmopolitan internationalization’ is central
to the cord-blood immunitary bioeconomy (2015: 6) because it
releases ‘immunized’ individuals or specific sub-populations from
their obligations to a broader political community. Importantly, this
goes beyond notions of blood economies as tied to national welfare-
state contexts or public/private distinctions – although both are
involved. We return to this later when we discuss the use of cord-
blood stem cells for culturing red blood cells, which we see as an
extension of this immunitary politics of blood. Thus the term ‘immu-
nity’, as used here, is primarily a political and not biological signifi-
cation, though it is applied in the context of health and medicine.
Nonetheless, in view of our discussion of cultured red blood cells,
we understand immunitary or immuno-politics to be the mitigation of
health or other biological risks to individuals, populations or popu-
lation subgroups through the application of biopower and/or biose-
curitization, specifically the regulation of various boundaries.
Biosecuritization can be understood as techniques to secure or isolate
bio-value from possible contamination, waste, or other forms of loss.
We use the term ‘bio-value’ here in the sense designated by Waldby,
as value that is ‘generated wherever the generative and transforma-
tive productivity of living entities can be instrumentalized along lines
which make them useful for human projects’ (2000: 33). We assume
that the creation of bio-value entails the application of technical
labour or techne¯ to living matter. Securitization processes usually
entail the separation of the biological material that has been desig-
nated as a potential asset or commodity from its original context, that
is, the donor body, and the subsequent creation of bio-commodities
that move through systems of exchange, sometimes structured as
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markets, sometimes not. The terms ‘asset’ and ‘commodity’ are not
interchangeable. An asset is a resource that has value or can be used
to generate value, and at the same time has value as property. A
commodity is an object that has been produced for exchange. An
asset increases in value as demand increases; a commodity decreases
in value as demand increases (law of demand) (Birch and Tyfield,
2013: 302). Human tissues may acquire a price even when the inten-
tion is not to trade them as commodities (Hoeyer, 2013). In short, in
the context of regenerative medicine, and cultured red blood cells
more specifically, immunity refers to securing objects that have bio-
value not only from loss but for the exclusive use of the immunized
individuals or group. This releases the immunized persons from obli-
gations stemming from sharing risks and resources with the broader
community, whether that is construed locally, nationally or globally.
At the centre of our analysis is an attempt to address questions
about how the discourses of immunity, biosecurity and privatization
of risk are linked to claims that the technology will address unmet
needs and promote social justice. We are concerned with both the
economic and socio-ethical value of cultured red blood cells while
not wishing to conflate them (Birch and Tyfield, 2013); we see these
aspects as interlinked. We argue that the introduction of cultured red
blood cells into national and global blood economies should be
understood as a form of biosecuritization and we ask what forms
of immuno-politics are enacted by this introduction.
To begin, we review current sociological understandings of rela-
tions within blood economies (exchange systems) and examine
claims that culturing red blood cells will revolutionize transfusion
medicine. We then discuss contemporary techniques being used to
develop ‘synthetic blood’ or cultured red blood cells from haemato-
poietic stem cells. This allows us to assess the extent to which cul-
tured red blood cells represent a reconfiguring of relations within
blood economies. The metaphor of ‘extending the gift’ (of blood
donation) has been used to describe techniques for cultured red blood
cells synthesis.1 However, this benevolent understanding of synthetic
blood production has also been countered by claims that the produc-
tion of synthetic blood per se threatens to weaken important kinship
bonds, create new market-driven flows of circulation and exchange
of bio-commodities, further ‘capitalisation of nature’ itself, and ulti-
mately threaten existing forms of social solidarity and increase
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experiences of alienation (Weston, 2013). We address this conflict of
interpretations.
Features of Contemporary Blood Economies
Relations between ‘donor’ and ‘recipient’ bodies in contemporary
blood economies have been widely discussed (Busby et al., 2014).
Conventional understandings of these relations in Western econo-
mies have drawn on notions of ‘gift relations’, where voluntary
unremunerated blood donation by ‘healthy’ donors is the model pre-
ferred by many policy makers and blood service providers (Titmuss,
1970; WHO, 2014). Such arrangements are seen as contributing to
social solidarity and shared values, foregrounding the altruistic moti-
vations of donors to ‘give life’ to others in need and creating bonds
between them. At the same time, the safety of the blood supply is
protected through careful screening of potential donors and exclusion
of ‘risky bodies’ where there may be risk of transmitting infection or
viral disease: biosecuritization (Kent and Farrell, 2015). Population-
wide participation in blood donation is still relatively low; in the
United States less than 10% of potential donors actually donate; in
the United Kingdom the figure is 3%.2
However, more complex dynamics are at play within transfusion
science and the global blood economy. There are, for example, other
models of blood services: replacement donation, that is, donation by
a family member; and paid donation – especially for plasma, along-
side industrial processing of plasma and manufacture of blood prod-
ucts (mostly in the US). Socio-cultural values shape these practices:
in some countries payment for blood is considered ethically accep-
table while in others blood donation from women is discouraged
(Kent and Farrell, 2015), particularly in the context of populations
affected by thalassaemia (Chattopadhyay, 2006). The exclusion of
some groups from becoming blood donors (known as donor deferral),
such as men who have sex with men (Berner, 2011; Galarneau, 2010;
Hurley, 2009) or migrants (Polonsky et al., 2011) draws on culturally
constructed concepts of risk (Strong, 2009) and is an example of the
biosecuritization of the blood supply.
Against this background, it has been suggested that the ‘production
of cultured red blood cells from stem cells holds the promise of
revolutionizing transfusion medicine and the existing red blood cell
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supply system’ (Bouhassira, 2012: 928). This promise of a ‘revolu-
tion’ draws on particular understandings about what is new about the
production of cultured red blood cells and resolution of major tech-
nical and social issues.
The strategic aims of producing cultured red blood cells at scale
are framed in several ways. First, ‘synthetic’ or ‘cultured’ blood has
been framed as a safer alternative to conventional blood donation.
Compared to the risks of transmitting infection via use of donated
blood, ‘ex vivo production of red blood cells in the laboratory can be
rigorously monitored and controlled to eliminate infectious risks’
(Shah et al., 2014: 347). Unlike donated blood, cultured red blood
cells can be understood as a mechanism of biosecuritization insofar
as they supposedly mitigate risk, not just to potential end users, but to
the blood supply itself. In this framing, the technical control of cell
differentiation, expansion and scale-up are presented as less risky
than the screening, processing and distribution of donor blood. This
claim merits closer analysis. The potential risks of using donated
blood are, in many countries, mediated by screening of donors, pro-
tocols for exclusion of those deemed unsuitable to donate, quality
systems for the management and processing of donated blood sam-
ples, and training for health professionals administering blood-based
therapies, together with monitoring of adverse incidents.3 In Europe,
blood donation and blood products are highly regulated (Farrell,
2012). In the United States, the Center for Biologics Evaluation and
Research regulates the collection of blood and blood components for
use in both transfusion or for the manufacture of pharmaceuticals.4
Second, proponents of cultured blood manufacturing also argue that
current arrangements for the collection and distribution of blood and
blood products are inadequate to meet demand, inefficient in reach-
ing those who need it most, risk transmitting disease, and cause
additional problems for those with chronic blood disorders due to
the proliferation of antigens in response to multiple transfusions.
However, this narrative conflicts with practices where target groups
for early trials of cultured red blood cells are patients with rare blood
groups and inherited blood disorders. Moreover, while publicity fre-
quently emphasizes that red blood cell manufacture could address
supply shortages,5 fewer scientists or clinicians argue that cultured
red blood cells could replace blood services reliant on donated blood.
Thus the claim that cultured red blood cells could represent a viable
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alternative to large-scale blood donation remains, for the time being,
questionable. Third, according to the United Kingdom’s (UK) NHS
Blood and Transplant service, cultured red blood cells are targeted
towards those with rare blood groups for whom blood is in short
supply, and those with blood disorders requiring frequent blood
transfusions. Cultured red blood cells could reduce the effects of
sensitization and iron loading among these patients.6 Finally it has
been suggested that the costs to the UK national blood services of
importing blood products derived from stem cells could be reduced
(Williams, 2015). It is important to situate these claims in the context
of global blood economies since it has been suggested that research
initiatives in the UK are targeting wider shortages.7
Globally, demand for blood and blood products is growing and
there are unmet needs. Factors determining this demand are (a)
demographic; (b) clinical – diagnostic and therapeutic possibilities;
(c) institutional or organizational, that is, to do with the infrastructure
to deliver effective blood services. A review of World Health Orga-
nization data (WHO, 2014) indicates that patterns of donation and
use vary. On the supply side, over half of blood donations are in high-
income countries, where only 18% of the world’s population live.
Between 2004 and 2012 blood donations increased by 25%. In 73
countries, over 90% of blood collected is via voluntary unpaid blood
donation, but 72 countries collect most blood from family/replace-
ment or paid donors. Most countries (113/156) import plasma-
derived products. On the demand side, ‘in low-income countries up
to 65% of blood transfusions are given to children under 5 years of
age: whereas in high-income countries the most frequently trans-
fused group is over 65 years of age, accounting for up to 76% of all
transfusions’. Pregnancy-related complications are also a common
cause for transfusion in low-income countries (Shah et al., 2014). In
wealthy countries, demand for blood products is increasing as demo-
graphic change means an ageing population, while declining birth
rates suggest there will be fewer donors (Seifried et al., 2011; Shah
et al., 2014). Some estimates suggest that in light of this changing
demographic profile, ‘even in developed countries where the supply
is currently adequate the supply of blood will be insufficient by 2050’
(Shah et al., 2014: 346). Consequently, securing the future blood
supply is a high priority for many countries and national policy
development, building appropriate national infrastructure and
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national self-sufficiency based on voluntary unpaid donation is being
promoted (WHO, 2014).
Clinical practice also shapes demand and the use of blood or
plasma products. For example, patients with haemolytic diseases,
when regularly transfused, can become sensitized to antigens that
are not normally reactive, which creates demand for ‘more precise
matching’ (Bouhassira, 2012). Increased sensitivity can make treat-
ment difficult and requires greater selectivity of the donated blood in
order to avoid complications. Incidence of inherited blood disorders
such as sickle cell disease (SCD) or thalassaemia varies across coun-
tries and population groups.8 Both these haemoglobin diseases have
been ‘ethnicized’ and racialized (Carter and Dyson, 2011; Dyson,
1998). Sickle cell ‘is a disease that has attracted the epithet of being
ethnically specific, one that “naturally” but superficially has come to
be associated with Black African ancestry’ (Carter and Dyson, 2011:
947). Medical knowledge about these genetic diseases has mapped
them onto ‘ethnic groupings’ relying on racist and essentialist
assumptions about the link between genetics, ancestry and kinship.
In the UK, thalassaemia beta major affects an estimated 1000 people,
who require blood transfusion throughout their life. Patients with
thalassaemia or SCD are most likely to receive cultured red blood
cells during early trials (NHS Blood and Transplant, 2015), though
the first human trial in the UK, due to begin in 2019, will be in
healthy volunteers.9
Causes of failure in the blood supply can relate to shortages of
stocks associated with falling donation rates or poor national infra-
structure, poor quality management procedures which may lead to
contaminated blood products, or poor clinical practices deployed in
the administration of blood products or other adverse incidents in
patient recipients. Regulatory failure may also lead to problems, as
illustrated in the 1980s and 1990s, when blood contaminated with
HIV and hepatitis C entered the supply (Archer, 2009; Farrell, 2012;
Penrose, 2015). So far we have confined our discussion to adult
blood donation, later we will turn to cord-blood banking.
Historical accounts suggest that substitutes for blood are not a new
idea. Since the beginning of the 20th century, when understanding of
blood group antigens emerged, blood cross-matching was seen as
important in developing blood technologies.10 Blood banks devel-
oped in the interwar years as storage methods improved. But the
8 Body & Society XX(X)
quest for alternatives to donated blood continued. Weston (2013:
247) suggests that ‘the quest for synthetic blood participates in a
broader capitalization of nature that promises to domesticate kin-
ship’. Before responding to this, let us first describe the technology
in more detail.
Culturing Red Blood Cells – Technology Development
There have been various attempts to develop different types of ‘syn-
thetic blood’ or blood substitutes. Acellular blood substitutes (some-
times referred to as ‘artificial blood’) potentially have a number of
functional advantages over donated blood – they would not require
cross-matching or compatibility testing, would be suitable for long-
term storage, be able to survive in vivo for several weeks before
being excreted, be free of side effects, free of pathogens, and trans-
port and deliver oxygen to the tissues (Squires, 2002). Since the
1970s, attempts to produce alternatives to haemoglobin found in red
blood cells to take up, transport and deliver oxygen to tissues have
presented technical challenges. South Africa and Russia approved
products such as Hemopure, a stabilized bovine haemoglobin11 for
clinical use (Chang, 2012; Ferguson et al., 2008; King, 2013).12 In the
USA, Northfield Laboratories developed and trialled Polyheme, a
product derived from modified human haemoglobin for use in resus-
citating trauma patients but ceased production in 2009 whenmarketing
authorization was refused (Apte, 2008; Kipnis et al., 2010). Substitutes
using perflourocarbons, a synthetic compound in solution and oxygen
carrier, have also been controversial but considered potentially useful
(Barbosa et al., 2009; Spahn, 1999). Some have suggested that sugar
beets could be used in producing a blood substitute.13
The need to resuscitate wounded persons in war conflict zones has
been a key driver for some of these initiatives, but more recently
techniques to develop ‘synthetic blood’ have centred on the culturing
of red blood cells for broader application. Worldwide, a number of
research teams (Anstee et al., 2012; Douay, 2012; Kim, 2014; Naka-
mura, 2008) have explored producing cultured red blood cells for
transfusion, requiring a high level of investment for laboratory stud-
ies, scale-up and clinical trials (Migliaccio et al., 2012). Teams use
different starting materials and methods. The Bristol Blood and
Transplant Research Unit14 group uses haematopoietic stem cells
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obtained from adult donor blood and umbilical cord blood. Our focus
in this article is on these two sources. We do not discuss the use of
human embryonic stem cells or induced pluripotent stem cells as
used by the Bloodpharma project in Edinburgh, UK, or the chal-
lenges of scale-up or translation (King, 2013; Lapillone et al.,
2010; Mazurier and Douay, 2013; Mittra et al., 2014; Mountford
et al., 2010; Mountford and Turner, 2011; Ramesh and Guhathakurta,
2013; Trakarnsanga, 2014).
Breaking Bonds, Alienation, Biosecuritization and
Immuno-politics
Given this institutional and technological context, how best to under-
stand where cultured red blood cells fit into the contemporary politics
of blood economies? In Titmuss’s (1970) influential model of the gift
relationship, through which blood donation is most often framed,
voluntary unpaid blood donation is tied to notions of citizenship and
social solidarity, underpinning certain functions of the welfare state
in Western economies. Commodity-based systems (as characterized
by blood services in the US), by contrast, represent a market-based
model of exchange distinct from the welfarist example (Migliaccio
et al., 2012). But contemporary blood economies are almost always
characterized by the coexistence of gift and commodity or welfarist
and market-based forms of exchange (Waldby and Mitchell, 2006).
In the UK, for example, while adult blood donation is unremunerated
and national blood services are not for profit, an internal market
based on ‘cost recovery’ operates within the NHS for blood products
and participates in the broader technoscientific enterprise and polit-
ical economy through the exchange of materials, information, equip-
ment and knowhow. Simultaneously, the NHS imports a wide range
of commercially produced plasma-derived products. Modern trans-
fusion services, banking, and synthesis techniques entail compart-
mentalization and commodification as essential aspects of the
biosecuritization necessary for the functioning of blood economies.
Public and private sectors overlap here and blood flows between
them, the same holds for cultured red blood cells, and importantly
the source materials for such cells. For this reason, parsing the pol-
itics of cultured red blood cells through a neat public/private distinc-
tion is not adequate.
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Weston’s (2013) argument that the ‘quest for synthetic blood’ is a
continuation and development of the ‘alienation’ inherent in other
forms of blood storage and transfusion, and more broadly in ‘biose-
curitization’, is the most thorough attempt to analyse the social
implications of synthetic blood production and entrance into blood
economies. She contends that the drive towards the development of
synthetic blood and its introduction into the blood economy restruc-
tures social relations: ‘taming kinship’ by dissolving direct rela-
tions between blood donors and recipients, undermining
‘naturalized’ familial and blood ties. The appeal of blood synthesis,
she argues, stems from ‘an attempt to evade or renegotiate the
imperatives of [ . . . ] other’ types of synthetic kinship structures.
Her concern is for certain forms of ‘kinship’ that were previously
facilitated by regimes of blood transfusion gift economy – partic-
ularly vein-to-vein transfusion. This argument, we think, functions
more as a critique of biosecuritization than of cultured or synthetic
blood per se. We understand ‘kinship’ here to mean not just familial
ties but other forms of community and social solidarity. Tracing the
purported alienation and abstraction of blood transfusion practices
through the establishment of national blood banks she observes how
blood shortages are construed as deficits in bank stocks, despite the
plentiful blood in the veins of the population. For example, donor
recruitment drives draw on a discourse of face-to-face relations
between donors and recipients and obscure the circumstances of
the production and marketing of blood products within capitalist
economies. Moreover, while the discourse of ‘the gift of life’
permeates calls for donation, commodification of blood is, at the
same time, a primary aim in the dynamics of all contemporary
blood economies, including efforts to develop scalable cultured red
blood cells.
We suggest that her critique of synthetic blood as a form of
alienation deploys the concept of alienation in a manner that is not
appropriate to the question of cultured red blood cells per se. Wes-
ton’s focus on concepts of alienation and commodification in the
production of biocapital deploys Marx’s concept of alienated
labour: ‘alienation can be devastating, creating what Marx called
a “realm of estrangement” that separates people from their life
activity as well as one another’ (Weston, 2013: 251). But does this
category of alienation apply as cleanly to the manufacturing of red
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blood cells and the introduction of synthetic blood into blood
economies as Weston suggests?
Weston is correct to say that the concept of alienated labour
applies to all wage labour within capitalist modes of production.
Alienation, in this context, refers to the separation of a person from
relations and functions that are proper to the person qua human being
and necessary to her flourishing. Alienation is thus experienced as
both deprivation and lack. Moreover, it refers to a phenomenology
(i.e. subjective experience) and a set of objective conditions pertain-
ing to what a human properly is and should be able to do. InWeston’s
account, the introduction of cultured red blood cells threatens to
alienate subjects from kinship relations that are constitutive of some
dimension of their personhood. Her emphasis on compartmentaliza-
tion suggests that her focus is on a substance or material base as the
object of alienation rather than a set of functions and relations. The
blood ceases to be a part of the embodied person, and subsequently
part of a symbolic web of kinship relations, and instead becomes
‘biocapital’ (living matter that is used to generate income or value).
Weston’s concern is that kinship relations are weakened by the
potential diminishing of the symbolic value of blood relations,
including transfusions, within certain populations: ‘taming kinship
relations through the commodification of blood may not have uni-
versal appeal, especially for groups whose ethnicity and/or nation-
ality is bound up with the valorisation of family’ (Weston, 2013:
246). Two discourses seem to be combined here: a concern for the
weakening of certain types of kinship relations that may underpin
national or other communitarian imaginaries, and a concern about
transformation into assets and/or commodification of blood and
blood products within biocapital market economies, where biosecur-
itization provides the impetus for the further development and
growth of these processes.
Pertaining to the first discourse, to the (questionable, considering
how little of the population participates) degree that blood gift econo-
mies are constitutive, at least in part, of kinship relations linked to
ethnic and national communities, it is not clear that this is in any way
normative. As we described earlier, these blood gift economies tend
to be exclusive. Moreover, communities that privilege ‘sang’ over
other forms of civic solidarity also tend to be exclusive, often to the
extent of being oppressive, and in their refusal of other obligations or
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responsibilities towards persons outside of the community of blood
and soil. It is also not clear that there is any reason to privilege
kinship relations at ethnic or national level. Weston is admittedly
ambiguous on this point, both alluding to the presumed importance as
well as perhaps authenticity of these types of relation, while
acknowledging their potential for becoming exclusionary. She
acknowledges that the abstraction of blood products from their
source (the direct donor or the source material for cultured red blood
cells) can undermine objectionable obstacles, for example, racism
based on a fetishization of blood ties to donation and transfusion:
‘transfer of blood ends up generating a kind of race/class solidarity,
figured in kinship terms, that no amount of talk or union organising
had managed to produce’ (Weston, 2013: 248).
In this example, the sacrifice across fetishized bloodlines (race)
has the symbolic force of generating new forms of solidarity, for
example, class over race. There is nonetheless an important ambi-
guity at play since the symbolic value of the sacrifice – in this
instance giving blood – is amplified by precisely the fetishization
of blood that the example is meant to downplay or overcome. A
more effective line of approach might have been to focus on the
more general link between sacrifice and solidarity in the gener-
ation of civic solidarities. We use the term ‘generation’ here
because there also seems to be present in Weston’s analysis an
assumption of the natural givenness of certain kinship relations
and not others; hence the distinction between natural and syn-
thetic kinship, which is maintained throughout her paper. Weston
does acknowledge that even ‘the most naturalised of kinship ties
must be synthesised in some sense, insofar as they are meaning-
fully constituted through culturally and historically located prac-
tices’ (Weston, 2013: 245).
The ‘bleed for England’ blood donation campaign launched by the
NHS Blood and Transplant service, in parallel with the 2015 Rugby
World Cup (hosted in England), provides a good example of the
ambiguity in these overlapping concepts of kinship or solidarity. The
campaign implored English people to make a sacrifice – bleed – in
the form of blood donation for the good of the nation. The ambiguity
lies in this case not on the side of the act of blood donation but of the
community in question: England. Is it an exclusive ethno-national
community or an inclusive civic community? Imploring persons to
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give blood for the sake of an exclusive ethno-national community in
order to reaffirm the fetishized bonds of blood and soil is not,
normatively speaking, the same as imploring them to give blood to
generate bonds of civic solidarity within more inclusive forms of
liberal or republican community.
The further concern for commodification of the body, its parts and
processes is also subject to a conflation, this time with forms of
alienation and compartmentalization. The conceptual slippage vis-
a`-vis alienation lies in confusing alienation from a substance with
alienation from a function or relation. In the argument that all com-
partmentalization of the body into mechanical parts and synthesis of
blood products involves alienation, sits the presupposition of the
body as an organic whole grounded in a substance, rather than the
body as a set of functions that can be variously performed, not only
often in interchangeable ways but also by interchangeable parts.
There are not good reasons to say that the body divided into parts
is by definition alienated; to do so implies an unproblematic notion
of bodily integrity which has been challenged in discussions of
organ transplantation and cell technologies (Hoeyer, 2013; Sharp,
2013; Shildrick, 2010). By contrast, a body commodified in terms
of parts (e.g. organs) or functions (e.g. units of labour) exchange-
able within a market is by definition alienated. That the whole
analysable into parts functions as a whole in relation to its environ-
ment is not nullified by the division, but only by some kind of
operation wherein the body part or function is transformed into a
commodity or asset. Nor does the aim of substitution of matter or
parts presume the functional independence or self-containedness of
those parts, only their materiality and interchangeability within
constraints. Compartmentalization and substitution do not rule out
relatedness as Weston argues (p247), but rather rule out material
essentialism about the embodied human.
In our view, alienation may derive from the transformation into
assets or commodification of bodily parts and processes, not from
the compartmentalization itself. Neither the weakening of familial
or ethno-national kinship relations, nor the material compartmen-
talization of the body necessarily entail the alienation that Weston
seems to argue is inherent to the synthesis of red blood cells and
their entry into blood economies. Rather, cultured red blood cells
are not a form of alienation from the embodied person unless they
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become a condition for denying the proper functioning of the per-
son. For example, a situation wherein donated or even purchased
blood or blood derivatives are commodified in a blood economy
that some citizens do not have access to or have access to only by
way of some form of diminishment, such as working extra hours
and losing family time to pay for blood products synthesized from
donated materials. But the alienation here lies in the social relations
not in the intrinsic relations between the embodied citizen and the
cultured red blood cells. Thus we think that the commodification of
bio-objects and derivatives such as synthetic blood cultured from
stem cells can occur within institutional contexts that are not
alienated.
Institutions like NHS Blood and Transplant aim to mitigate the
possibilities of these types of alienation within a specified territory
and are central to the UK effort to manufacture cultured red blood
cells at scale and to distribute them. Consequently, any normative
analysis of cultured red blood cells must be parsed through an
understanding of varying institutional contexts. Though the pub-
lic–private distinction is not decisive, a distinction must nonethe-
less be made between welfarist and non-welfarist biopolitics, the
former oriented towards maximizing health outcomes and well-
being in an equitable fashion across a relevant population, and
hence mitigating risk of alienation. Both institutional contexts
entail commodification qua production for exchange, but the nature
and aim of this commodification is salient. Thus, the pivotal con-
sideration is the institutional context for the synthesis and conse-
quent commodification of cultured red blood cells, not the
distinction between natural and synthetic blood or biosecuritized
vs authentic transfusions. This institutional context and commodi-
fication of cultured red blood cells can be analysed via the concepts
of biosecuritization and immunity. Hence it remains salient to ask if
biosecuritization necessarily entails a ‘capitalization’ of the body
and a further ‘capitalization of nature’ that ‘promises to domesticate
kinship’? And, if so, does this in some way inhibit, limit or degrade
relations of solidarity regardless of the institutional context in
which it occurs? To address this question in the context of cultured
red blood cells, we focus on the institutional contexts of peripheral
and cord blood as stem cell sources for manufacturing cultured red
blood cells.
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Situating Cultured Red Blood Cells beyond Welfarist vs
Non-welfarist Binary Distinctions: Cosmopolitan
Immuno-politics
Stem cells obtained from adult peripheral blood or cord blood can be
used to produce cultured red blood cells. Both are collected by NHS
Blood and Transplant and the Bristol Blood and Transplant Research
Unit. We think that the normative question of biosecuritization, in
the context of the potential transformation of blood economies by the
development of cultured red blood cells, is closely related to the
political context of the source stem cells. Moreover, the debate sur-
rounding cord-blood banking is a helpful heuristic for understanding
issues that could arise in relation to the further development and
eventual deployment of cultured red blood cell technology. Brown
and Williams (2015) and Brown et al. (2011) have used the language
of immunity and immuno-politics (borrowed from Esposito) to
describe the political dimensions of cord-blood cell banking. Due
to the constant intermingling of public and private in the blood econ-
omy, they call into question the relevance of the public–private dis-
tinction to the political evaluation of cord-blood banking practices.
We will follow their lead here but try to maintain the relevance of
what we have called the welfarist–non-welfarist distinction,
acknowledging the frequent mixing of public and private in welfarist
institutional set-ups. Immuno-politics in this context entails a focus
on what borders of inclusion and exclusion are drawn in the produc-
tion and clinical use of cultured red blood cells per se, but more
specifically the manner of their institutional introduction into blood
economies. This refers to the original juridical sense of the terms
immunitas and communitas that we introduced in the beginning, but
the political significance of immunity increasingly refers to how
biological materiality appears as constitutive of political boundaries
of inclusion and exclusion. There is an important distinction between
the privatization of biological risk and the increased securitization of
cosmopolitan welfarist politics, that is, public health management
systems that do not deploy or operate under binary, for example
nationalized or racialized, self vs non-self immuno-politics. Within
the context of welfarist immuno-politics, biosecuritization can be a
form of immunizing a porous and immunologically diverse commu-
nity against dangers and risk, not against those simply conceived
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biopolitically as others in ethnic, national or economic terms (or
some combination). Moreover, it is the privatization of risk carried
out in ways that undermine the functioning of welfarist institutions
that creates the risk of a normatively problematic immuno-politics,
not a natural vs. synthetic distinction. The threat of a capitalization of
nature should be seen through this lens and not through a problematic
natural/synthetic distinction.
In view of this, we think that there is a politically salient distinc-
tion between different cell sources for cultured red blood cell tech-
nology, specifically haematopoietic stem cells from (a) donated
peripheral blood (from adults) and (b) cord blood. As we have seen,
the former mobilizes discourses of community and solidarity in a
conventional manner. The use of adult donor blood samples that
might otherwise be ‘wasted’ to produce cultured red blood cells is
construed as ‘extending the gift’ of donated blood. By describing
cultured red blood cells as a method for ‘extending the gift’, the
discourse of face-to-face relations and welfarist public health insti-
tutions are mobilized to revalidate donation practices and resist the
view that the technology can substitute blood donation. Claims that a
universal product could address shortages and niche needs within the
global blood economy foreground inclusivity and open access, con-
struct particular notions of ‘unmet need’ but also risk ignoring the
political realities of social inequality and difference.
By contrast, the use of stem cells from donated cord blood must be
understood within a very different institutional context. Cord blood
may be regarded as ‘on the borderlands between community and
immunity’ (Brown and Williams, 2015) a bio-object that straddles
both the public–private and welfarist–non-welfarist divide within
blood economies (Martin et al., 2008). Cord-blood banking has a
history based on the successful use of stem cells from cord blood for
transplantation, as an alternative to bone marrow transplants. Har-
vesting of cord blood for private banking is controversial among
clinical, policy and academic communities. There is concern that
procurement denies the baby important resources and interrupts the
clinical management of labour; second, in contrast to public banks,
which rely on altruistic donation, private, commercial cord-blood
banks encourage a kind of hoarding, a ‘miserly’ tendency to save
for an uncertain future (Fannin, 2013). Hoarding is thus an integral
part of, or at least not in contradistinction to the privatization of risk
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and could simply be understood as the transformation into stockpiled
assets. So while public cord-blood banks (like banking of adult donor
blood) rely on a welfarist ethical imperative to mitigate population-
wide health risks through altruistic allogeneic donation and public
risk-sharing institutions, private cord bloods mobilize a drive to
stockpile assets (withdraw from circulation) and alter the traditional
dynamics of welfarist risk-sharing by encouraging individuals to
essentially insure themselves or their families against potential future
health risks. This privatized and individualized form of biosecuriti-
zation enacts a very different form of immuno-politics than the pub-
lic welfarist version. Rather than seeking to secure an, at least
potentially, diverse political community against health-risk, the pri-
vatization of biosecuritization enacts a boundary of exclusion around
the family or other privately insured unit, immunizing or releasing
the privately insured unit from obligation or debt to welfarist risk-
sharing institutions. This is regardless of the fact that in the case of
private cord-blood banking the private investment is speculative and
relies on cord blood being exploited in the future, which may depend
upon public research investment. Thus, privatization of risk under-
mines the risk-pooling mechanisms of welfare-statist biopolitics,
while at the same time involving those institutions as essential parts
of the cord-blood economy and, in particular, the part most likely to
be instrumental in the future realization of the present investment
(the banking of the cord blood).
Thus, while we agree with Brown et al. that the cord-blood econ-
omy undermines any binary distinction between public and private
cord-blood banking and that ‘whether private or public, such banks
are immunitary ventures, stockpiles of immunity’ (Brown et al.,
2011: 1116), we maintain the importance of a welfarist–non-
welfarist distinction, all the while acknowledging that both
individual-private and public welfarist models of the cord-blood
economy remain ‘immunitary ventures’. There is no contradiction,
then, in acknowledging with Brown et al. that public cord-blood
banking can and often does function according to similar exclusion-
ary immuno-politics on a global scale. In this account, cord-blood
banks were set up to address inequalities in bone marrow transplan-
tation and the dominance of White Caucasian donors and under-
representation of certain ‘ethnic groups’. Cord-blood banks target
populations of under-represented groups who also have higher
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incidences of haemoglobinopathies and lower stem cell counts.
Paradoxically, though set up to address issues of social inequality and
justice, cord-blood banks appear to reproduce those inequalities. In the
US, despite attempts to enrol African American sickle cell families in
stem cell collection, few patients from these families receive trans-
plantations due to underlying ‘ethnoracial dynamics’ (Benjamin,
2013:115). In tracing the flows of cord blood globally, Brown and
Williams suggest that ‘cosmopolitan internationalization is central to
the underlying rationale and purpose behind the establishment of the
[cord-blood] immunitary bioeconomy’ (2015: 6) and that cord-blood
banking ‘subverts both the moral economies of the gift and the polit-
ical economies of the market’ (2015: 11) through an immunitary
regime which reconfigures colonialism by deploying the language of
‘race’ and ‘ethnicity’, and international registries that construct or
‘reassemble a globally distributed diasporic immunity’ (2015: 8). Bio-
logical immunity is politically drawn through the circulation of cord-
blood stem cells which are produced from women’s bodies.
Subsequently, we agree that any attempt to apply the binary public
vs private or welfarist vs non-welfarist distinction to the downstream
synthesis of cultured red blood cells from cord-blood harvested stem
cells would likewise run into the same issues that Brown et al. point
to in the practice of cord-blood banking itself. The issues pertaining
to the institutional and political context of the source materials of
cultured red blood cells will likewise apply to the cultured red blood
cells. However, beyond the issue of source materials and the
immuno-political regimes currently associated with them, we can
ask if cultured red blood cells, within a more general institutional
context fall within the logic of ‘cosmopolitian internationalism’ that
Brown et al. attach to cord-blood banking? By targeting populations
with rare blood groups and those with inherited blood disorders the
construction of these ‘niche markets’ for cultured red blood cells
(which may potentially include export across national boundaries)
pulls away from the universalizing discourse which heralds ‘syn-
thetic blood’ as a solution to global blood shortages. Rather, the
rationale for culturing red blood cells conceived of as a method for
facilitating more ‘precise matching’ (Bouhassira, 2012) draws on an
immunitary logic of self/non-self (better matched blood groups)
while at the same time constructing racialized global or cosmopolitan
networks of immunity.
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We can summarize how we understand the relation between the
institutional context of cultured red blood cells and the ‘cosmopo-
litan internationalist’ model of the ‘immunitary bioeconomy’ as
theorized by Brown and Williams: the analysis of cord-blood
banking brings into question the binary public vs. private or wel-
farist vs. non-welfarist distinction or models of immuno-politics,
in its place Brown and Williams (2015) and Brown et al. (2011)
develop the notion of a cosmopolitan internationalist immune pol-
itics, which involves both public institutions and the privatization
of risk. By extension, this is relevant to the discussion concerning
the immuno-politics of cultured red blood cells derived from
umbilical cord blood. So the analysis and evaluation of the
immuno-political context of cultured red blood cells, that is, pro-
duction and scale-up within the institutional context of NHS Blood
and Transplant, relates to the source materials. A discourse of
referring to the culturing of red blood cells as ‘extending the gift’
signals an intended extension of traditional nation-state-based wel-
farist discourses surrounding blood donation, and production of
blood products for use within the NHS. This intended extension
of the welfarist discourse of traditional blood donation is more
viable when the source materials are adult stem cells, procured
via traditional avenues of donation. The use of umbilical cord-
blood stem cells (even where they are donated to public banks),
by contrast, situates cultured red blood cells production in the
immuno-political context of cord-blood banking described above.
If the institutional context of cord-blood banking constructs a
network of racialized bodies and identities based on categoriza-
tions of immunity (blood grouping and matching), as Brown and
Williams argue, then, similarly, by drawing on a notion of ‘more
precise matching’ for those with haemoglobinopathies such as
sickle cell disease and thalassaemia and the construction of ‘niche
markets’ for cultured red blood cells to meet rare needs in the
international market, cultured red blood cells technology risks
reproducing exclusionary ‘cosmopolitan internationalist’
immuno-politics. Simply put, cultured red blood cells are not bio-
political or immune-political game changers but situate themselves
within existing institutional and political orders depending both on
source material and intended use and recipients.
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Conclusions
The manufacturing scale-up of cultured red blood cells depends on a
supply of allogeneic cord blood which, in the first instance, will be
sourced from NHS Blood and Transplant’s public cord banks, and
adult blood donations. The role of NHS Blood and Transplant is
crucial as a site for the production of cultured red blood cells but
also produces specific understandings of unmet need (Williams,
2015). While boundaries between public donation and benefit, and
generation of value are intertwined or entangled, institutionally NHS
Blood and Transplant remains within the frame of welfarist biopo-
litics. As a key partner in the UK research effort they lead and
support the scientific research, lead on the safety and clinical testing
of the cells, and on developing the manufacturing process to meet
regulatory requirements and to produce cultured red blood cells at
scale. So far it is unclear what the business model for future transla-
tion and diffusion of the technology might be but evidently this state-
funded institution has an infrastructure and expertise for producing
and distributing this product. Production of cultured red blood cells at
scale for transfusion and potential distribution via NHS Blood and
Transplant may be seen as an extension of the biopolitics of the
welfarist blood gift economy – via the ‘extending the gift’ trope.
We situate the current large investments by the UK’s NHS in the
development and scale-up of this technology of the culturing (man-
ufacturing) of red blood cells within the biopolitical landscape of
contemporary blood economies. Claims that cultured red blood cells
have the potential to address unmet social need and shortages in the
blood supply are frequently linked to the production of a universal
product which would be widely available and accessible. We think
such a claim underplays the significance of the international context
of blood service delivery within both welfarist and privatized profit-
driven, or what we call above ‘cosmopolitan internationalist’ models.
Both models utilize scientific and political techniques of biosecur-
itization and immunization. What we have argued here is that,
despite this, the distinction between welfarist and non-welfarist mod-
els is still salient, especially when considering the stem cell source
for cultured red blood cells. In our assessment of the concerns raised
that ‘synthetic’ blood could undermine naturalized forms of kinship
we concluded that so-called blood gift economies in the UK draw on
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ambiguous notions of community and civic solidarity which are
exclusionary and reaffirm the fetishized bonds of blood and nation.
Representations of cultured red blood cells as ‘extending the gift’
draw on these ideas of community and civic solidarity. It remains the
political and institutional context of the introduction of the technol-
ogy that matters most here.
Moreover, we suggested that it is not the material separation of
blood cells from the body which necessarily leads to alienation but
rather whether the proper function of a person is denied by institu-
tional arrangements. Neither do we see the key distinction to be
between natural vs synthetic blood. In our analysis, the central ques-
tions are what kind of immuno-politics are enacted by the introduc-
tion of cultured red blood cells into contemporary blood economies
as a form of biosecuritization and what kinds of immuno-politics are
materialized by practices of culturing red blood cells? The produc-
tion of cultured red blood cells within the institutionalist context of
welfarist public health systems may serve to prop up a normative
public/private distinction, wherein the public utilizes, not unproble-
matically, discourses of solidarity and ‘extending the gift’. But the
source material, adult stem cells or cord-blood cells, is relevant to
any eventual normative analysis of the institutional context of cul-
tured red blood cell production and utilization. It is, however, not the
only relevant factor; participation in blood donation programmes is
low in the UK (as elsewhere) and recruitment of cord-blood donors
targets ethnic groups in limited geographical areas. Target popula-
tions for the testing and use of cultured red blood cells are those with
inherited blood disorders such as sickle cell disease and thalassae-
mia, the very groups who are under-represented in the donor pool.
Recruitment of, and uptake by these target groups is likely to be
shaped by existing social and health inequalities. Or, to put it another
way, cultured red blood cell production, even within the institutional
context of NHS Blood and Transfer service, may still materialize a
form of cosmopolitan immuno-politics through the construction of
‘unmet needs’ of those whose haematological profile and health
status ‘naturalizes’ racial and ethnic divisions within an immunitary
bioeconomy. In short, the production of cultured red blood cells and
their movement through the blood economy and translation to the
clinic is unlikely to constitute a revolution.
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Notes
1. Thanks to Ash Toye, Deputy Director of the Bristol Blood & Trans-
plant Research Unit for this. http://bristol.ac.uk/btru/.
2. See: http://www.redcrossblood.org/learn-about-blood/blood-facts-
and-statistics and http://www.blood.co.uk/giving-blood/ (accessed 20
October 2015).
3. See: https://aic.mhra.gov.uk/mda/sabresystem.nsf/Login?%20Open
(accessed October 2015).
4. See: http://www.fda.gov/BiologicsBloodVaccines/BloodBlood
Products/
5. See: http://novosang.co.uk/media/wellcome-trust-funds-research-culti
vate-red-blood-cells (accessed March 2016).
6. For a lay description of thalassaemia, see: http://www.thalassemia.org/
learn-about-thalassemia/about-thalassemia/ screening in the UK http://
sct.screening.nhs.uk/statistics (accessed June 2015).
7. See: http://novosang.co.uk/media/wellcome-trust-funds-research-culti
vate-red-blood-cells and https://wellcome.ac.uk/press-release/first-
volunteers-receive-blood-cultured-stem-cells-2016 (both accessed
March 2017).
8. See: http://www.thalassemia.org/learn-about-thalassemia/about-thalas
semia/ and http://sicklecellsociety.org/ (accessed July 2015).
9. See: http://www.bristol.ac.uk/btru/ for a description of the RESTORE
trial (accessed March 2017).
10. See: http://www.redcrossblood.org/learn-about-blood/history-blood-
transfusion or http://www.blood.co.uk/about-blood/history/ (accessed
March 2015).
11. See: http://www.hbo2therapeutics.com/products/general.php for
details of the current manufacture of Hemapure for human use
HBOC-201. The product has not been approved for routine clinical
use in the US or Europe (accessed March 2015).
12. See: http://www.perftoran.ru/index.php/en/for-physicians/about-perf
toran for details of product licensed in Russia (accessed March 2015)
Kent and Meacham 23
13. See: http://www.lunduniversity.lu.se/article/sugar-beets-could-
become-blood-substitute (accessed March 2015).
14. The NIHR Blood and Transplant Research Unit in Red Blood Cell
Products, funded by the National Institute for Health Research
(NIHR) is a partnership between the University of Bristol and NHS
Blood and Transplant (NHSBT) in collaboration with the University
of Warwick, the University of Bath and the University of the West of
England. http://www.nihr.ac.uk/funding/blood-and-transplant-
research-units and http://www.bristol.ac.uk/btru/ (accessed March
2017).
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